Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

Inclusion Criteria: * Signed informed consent. * 18 years of age, or older. * Capable of completing the diary card. * Ability to complete the HRQL questionnaires. * A clinical diagnosis of a chronic condition (e.g., osteoarthritis or rheumatoid arthritis) that requires continuous daily NSAID treatment for at least 7 months. Daily NSAID treatment is defined as taking the prescribed dose for at least 5 of 7 days in any given week and can include COX-2 selective NSAIDs, multiple NSAIDs, and high-dose aspirin (\>325 mg/day). * Daily NSAID treatment dose and type: (Must have been stable for at least 4 weeks prior to baseline endoscopy and; Are expected to remain stable for the duration of the study. and; Must be administered orally for the duration of the study. If more than one type of NSAID treatment is used, at least one type must be given orally.) * Hp negative by UBT, serology or biopsy based test, at visit 1. Exclusion Criteria: * Current, or history of, gastric or duodenal ulcer * Current, or history of, esophageal, gastric or duodenal surgery. * History of GERD, not associated with NSAID use. * Pain, discomfort or burning in the upper abdomen precipitated by exercise or relieved by defecation. * Pain, discomfort or burning in the upper abdomen not associated with the use of NSAIDs, including COX-2 selective NSAIDs, as judged by the investigator. * Endoscopic Barrett's esophagus(\>3 cm) or significant dysplastic changes in the esophagus.